GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

计划入组 48 人 · 首次发布于 2018 年 7 月 3 日

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

计划入组 35 人 · 首次发布于 2023 年 10 月 16 日

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

计划入组 65 人 · 首次发布于 2007 年 8 月 27 日

FAP-DR5

DR5-12D

Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio)

DRI HEALTHCARE TRUST

Canada

DRC CO., LTD.

Japan

Prof. Dr. Dr. Ursula Mirastschijski

Germany

Fusion Antibodies Advances DR5 Humanised Antibody for Treatment-Resistant Cancers with Extended Grant Support

Inhibrx to Present Topline Results from Registrational Chondrosarcoma Trial of Ozekibart

Inhibrx to Present Clinical Update on Ozekibart in Late-Line Colorectal Cancer